Dong Wen

Dongwen Biopharmaceutical is a China-based biotechnology company focused on the discovery and development of next-generation antibody-drug conjugates (ADCs) for the treatment of cancer. Founded in 2021 by Dr. Wen Dong, a veteran of ADC pioneer Seagen, the company leverages a proprietary technology platform designed to enhance the stability and therapeutic index of ADCs through site-specific conjugation and optimized linker-payload systems. Headquartered in the Suzhou Industrial Park (Biobay), Dongwen aims to address the limitations of current ADC therapies, such as off-target toxicity and narrow therapeutic windows, by employing advanced chemical and biological engineering. Its pipeline includes several candidates targeting solid tumors, including programs directed at well-validated antigens like HER2 and TROP2, which are currently in the pre-clinical and discovery phases. The company has successfully raised venture capital from prominent investors to advance its internal R&D and establish itself as a leader in the competitive ADC landscape.